Live Breaking News & Updates on Head Of Global Pharmaceutical Development

Stay updated with breaking news from Head of global pharmaceutical development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

BioSpace Movers & Shakers, June 4

Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers. ....

Wills Eye Hospital , United States , M Karen Newell Rogers , Myers Squibb , Denise Strauss , Marc Semigran , Davidc Hanley , Eric Castaldi , Jen Hong , Meagher Flom , Marc Massiot , Newell Rogers , Robin Knifsend , Theodore Reiss , Jeff Cruikshank , Evelo Biosciences , Judith Robertson , Alexander Ferdon , Mike Nohaile , Nuvation Bio , Adam Drapczuk , Mark Plinio , Julia Haller , Antoni Ribas , Anne Walker , Ann Lee ,

BioSpace Movers & Shakers, June 4

Published: Jun 03, 2021
By Alex Keown
180 Life Sciences Russell T. Ray and Teresa DeLuca were appointed to the board of directors of 180 Life Sciences. Ray was formerly Managing Director and co-Head of Global Health Care at Credit Suisse First Boston Corporation. More recently, Ray was a Partner and Senior Advisor to HLM Venture Partners, a health care-focused venture capital firm. He currently serves on the board of directors of Merrimack Pharmaceuticals, Inc. DeLuca comes to 180 Life Sciences as both a public independent board director and former senior executive Chief Medical Officer. Her most recent role was at Columbia University as Managing Director of NY Life Science Venture Fund. ....

Wills Eye Hospital , United States , M Karen Newell Rogers , Myers Squibb , Denise Strauss , Marc Semigran , Davidc Hanley , Eric Castaldi , Jen Hong , Meagher Flom , Marc Massiot , Newell Rogers , Robin Knifsend , Theodore Reiss , Jeff Cruikshank , Evelo Biosciences , Judith Robertson , Alexander Ferdon , Mike Nohaile , Nuvation Bio , Adam Drapczuk , Mark Plinio , Julia Haller , Antoni Ribas , Anne Walker , Ann Lee ,

Nuvation Bio Appoints David C. Hanley, Ph.D., as Chief Technical Operations Officer

Published: Jun 01, 2021
Experienced technical operations and CMC leader brings scientific and strategic expertise in oncology drug development and life cycle management
NEW YORK, June 1, 2021 /PRNewswire/
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of David C. Hanley, Ph.D., as Chief Technical Operations Officer, joining the Company s executive management team. In his new role, Dr. Hanley will oversee all early- and late-stage pharmaceutical development and operations, including supply chain, product development and manufacturing efforts, and work closely on commercial planning with Quality, Regulatory Affairs, Clinical Development and Clinical Operations teams. ....

New York , United States , San Francisco , Leo Vartorella , Nuvation Bio , Davidc Hanley , Head Of Global Pharmaceutical Development , Medicines Company , Regulatory Affairs , University Of Utah , Virginia Commonwealth University , Drug Administration , Global Pharmaceutical Development , Nuvation Bio Inc , Prnewswire Nuvation Bio Inc , Radius Health Inc , Medivation Inc , Clinical Development , Chief Technical Operations Officer , Clinical Operations , Senior Vice President , Bioxcel Therapeutics , David Hung , Radius Health , Vice President , Pharmaceutical Sciences ,